Catalent launches softgel products at CPhI: one vegetarian, one anti-abuse

Loading the player...

Catalent has announced two new softgel solutions as it adds greater versatility to its Advanced Technologies Business Unit.

“Softgel has been the backbone of the company for many decades now,” Will Downie, Senior VP of Global Business at Catalent told this publication in Frankfurt yesterday, as it showcased two new softgel offerings.

The first is the Optishell which uses seaweed in place of gelatin, offering a capsuling solution for those who don’t meat. The technology also allows high melting point, high pH or semi-solid APIs to be put into softgels.

With OptiGel Lock, various resins and delivery technology are used to stop potential abusers extracting the API and injecting them intravenously, Downie said.

The two new products all provide “more versatility” for Catalent’s… global softgel customers and this business sits alongside the Advanced Technologies Business Unit, formed earlier this year. “We brought together our sterile technology, together with our modified release, controlled release and Zydis technology, under one umbrella.”

Downie also spoke about recent acquisitions in the softgel field, in China and Brazil, explaining how Catalent is “moving with the market dynamics … as economies change and emerging markets become more important.”

This article was corrected from the original as Downie was talking about the Optishell technology rather than the Optigel Bio, as was first reported. The Optigel Bio is another new product for the delivery of macro molecules.

Related News

Catalent clinical supply plant opens its doors in China

Catalent clinical supply plant opens its doors in China

Catalent's $100m IPO could be five times that, says investment firm

Catalent looks to go public with $100m IPO

(Picture credit: Melissa Wiese)

Europe slow to adopt anti-abuse formulations and tech, says expert

Acura pays Pfizer $2m to buy back anti-abuse tech and Oxecta drug

Acura pays Pfizer $2m to buy back anti-abuse tech and relaunch Oxecta drug

Catalent to make anti-hayfever drug containing ragweed extract for Merck & Co.

Merck & Co. contracts Catalent to make sublingual hayfever drugs

Elite's ELI-200 candidate contains naltrexone which is released when crushed or dissolved and blocks the euphoric reaction of the opioid on a potential abuser

Elite opts to keep anti-abuse opioid manufacturing in-house

Catalent bringing in the closing of the New York Stock Exchange on Monday.

Catalent sees growth strengthened by international softgel markets

Catalent boosts services at Eberbach, Germany site

Catalent to offer integrated services in Germany through softgel expansion

Police Facebook campaign calls on Pharma to help tackle opioid abuse

Police Facebook campaign calls on high-paid Pharma CEOs to tackle opioid abuse

Growing demand for vegetarian capsules despite their cost, Capsugel

Growing demand for vegetarian capsules despite their cost, says Capsugel

Related Products

See more related products